분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-04-10 08:47:08 , Hit : 600
 Nature Methods retracts CRISPR study

Biocentury

https://www.biocentury.com/bc-extra/preclinical-news/2018-03-30/nature-methods-retracts-crispr-study

6:47 am JST  |  Mar 31, 2018  |  BC Extra  |  Preclinical News
by Allison Johnson


On Friday, Nature Methods retracted a 2017 CRISPR-Cas9 gene editing letter days after the paper's authors walked back on their findings in an expanded study published in the preprint journal bioRxiv.

The 2017 Nature Methods paper from researchers at Stanford University, Columbia University and University of Iowa claimed CRISPR gene editing led to an unexpected high level of off-target mutations. In the retraction, the journal said there were insufficient data to support the claim and cited the need for a control comparison between parent and offspring mice to determine whether natural genetic variation clouded the authors' interpretation of CRISPR-mediated off-target mutations (see BioCentury Extra, May 30, 2017).

The journal said two of the six study authors agreed with the retraction, and four did not. It did not provide the authors’ reasoning.

The findings of the group's expanded bioRxiv study, which used two mouse strains with different genetic backgrounds, suggested CRISPR editing may not introduce numerous and unintended mutations (see BioCentury Extra, March 26).

Others, including executives at Editas Medicine Inc. (NASDAQ:EDIT) and Editas advisor George Church, have published studies showing that natural genetic variations prior to CRISPR treatment were likely the cause of observed variants (see BioCentury Extra, June 22, 2017).

Based on public responses to the original Nature Methods study, the journal published an editorial note in June stating the conclusions of the paper "are subject to criticisms that are being considered by editors," and issued an editorial expression of concern in July (see BioCentury Extra, June 16, 2017).

Stanford professor Vinit Mahajan, a corresponding author on the Nature Methods paper, told BioCentury his group is using whole genome sequencing on additional CRISPR treated mice to elucidate CRISPR's off-target effects.








1227   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 570
1226   Alcoholism Gene Therapy Shows Promise  이성욱 2017/09/20 583
1225   CRISPR Used in Human Embryos to Probe Gene Function  이성욱 2017/09/22 584
1224   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 591
1223   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 591
  Nature Methods retracts CRISPR study  이성욱 2018/04/10 600
1221   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 607
1220   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 610
1219   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 614
1218   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 641
1217   DNA Construction  이성욱 2017/09/15 661
1216   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 666
1215   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  이성욱 2018/09/12 671
1214   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 689
1213   First CAR T-Cell Therapy Approved in U.S.  이성욱 2017/09/01 692
1212   UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 696
1211   [바이오 업계 소식: From Startups to Moguls] CRISPR-Cas9에 대한 경고와 업계 반응  이성욱 2017/06/14 702
1210   Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 703
1209   Mammalian Immunity: What’s RNAi Got to Do with It?  이성욱 2017/07/25 705
1208   코오롱 인보사허가  이성욱 2017/07/12 706

[1][2] 3 [4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN